2. UroToday Home
  3. Video Lectures

ESMO 2020 Videos

Discussing the Efficacy and Safety from Results of the Dose Escalation Arm of AMG 160, a Bispecific T-Cell Engager (BiTE) Immune Therapy Targeting PSMA for Metastatic Castration-Resistant Prostate Cancer - Ben Tran, Oliver Sartor, and Neal Shore
November 30, 2020
Details
Preliminary Efficacy of AMG 160 in Metastatic Castration-Resistant Prostate Cancer, Interim Results From the Phase 1 Study - Tanya Dorff
November 16, 2020
Details
A New Class of Immunotherapeutic Molecules for Metastatic Prostate Cancer in Development - Karim Fizazi
November 5, 2020
Details
IPATential150: Phase III Study of Ipatasertib plus Abiraterone vs Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer - Cora Sternberg
October 28, 2020
Details
The Final Results of KEYNOTE-361 - Ajjai Alva
October 26, 2020
Details
Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde
October 21, 2020
Details
Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Can Be Preselected to Maximize Benefit of Olaparib - Maha Hussain
October 16, 2020
Details
Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar
October 14, 2020
Details
Outcomes Related to Cancer Treatments in Patients with COVID-19 from the CCC19 Registry Analysis- Ali Khaki, Jeremy Warner & Petros Grivas
October 6, 2020
Details
Abiraterone Acetate plus Prednisolone for Hormone-Naïve Prostate Cancer: Long-Term Results from Metastatic (M1) Patients in the STAMPEDE Randomized Trial - Nicholas James
October 6, 2020
Details
Durvalumab Plus Tremelimumab for Frontline, Metastatic, Urothelial Cancer, The Phase III DANUBE Trial - Thomas Powles
October 6, 2020
Details
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
October 5, 2020
Details
ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas
September 29, 2020
Details
ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks
September 28, 2020
Details
ESMO 2020: CheckMate-9ER Study of Nivolumab Combined With Cabozantinib Vs. Sunitinib in Participants With Previously Untreated mRCC - Toni Choueiri
September 28, 2020
Details